Cargando…
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway
PURPOSE: Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs. The aims of this study were to assess the efficacy of the combination of src inhibition and gemcitabine in gemc...
Autores principales: | Wu, Zhen-Hua, Lin, Chen, Liu, Ming-Ming, Zhang, Jian, Tao, Zhong-Hua, Hu, Xi-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201240/ https://www.ncbi.nlm.nih.gov/pubmed/28036386 http://dx.doi.org/10.1371/journal.pone.0169230 |
Ejemplares similares
-
Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity
por: Mhone, Thomas Gabriel, et al.
Publicado: (2022) -
Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022) -
Gemcitabine resistance in triple-negative breast cancer cells can be reverted by Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol
por: Zhao, Yan, et al.
Publicado: (2020) -
Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
por: Manouchehri, Jasmine M., et al.
Publicado: (2022) -
Cyr61 as mediator of Src signaling in triple negative breast cancer cells
por: Sánchez-Bailón, María Pilar, et al.
Publicado: (2015)